Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: Novel insights from interspecies comparison

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 1, 2012, Pages 215-237

  Calvisi, Diego F ^a   Frau, Maddalena ^a   Tomasi, Maria L ^a   Feo, Francesco ^a   Pascale, Rosa M ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Hepatocarcinogenesis; Interspecies comparison; MicroRNA; Prognostic marker; Signal transduction; Therapeutic target

Indexed keywords

AMYLO 1,6 GLUCOSIDASE; AZACITIDINE; CARBOHYDRATE; DOXORUBICIN; FUMARYLACETOACETASE; GLUCOSE 6 PHOSPHATASE; HIPPO PROTEIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON; LIPID; METHIONINE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PORPHOBILINOGEN DEAMINASE; PROTEASOME; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; SONIC HEDGEHOG PROTEIN; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UROPORPHYRINOGEN DECARBOXYLASE; VINCRISTINE; WNT PROTEIN;

AMINO ACID METABOLISM; ANTINEOPLASTIC ACTIVITY; CARBOHYDRATE METABOLISM; CELL CYCLE; DRUG RESEARCH; DRUG TARGETING; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LIPID METABOLISM; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RODENT; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; UPREGULATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; SIGNAL TRANSDUCTION;

ERINACEIDAE; RODENTIA;

EID: 84860790712     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.04.003     Document Type: Review

References (397)

1. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
2. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
3. Feo F., Pascale R.M., Simile M.M., De Miglio M.R., Muroni M.R., Calvisi D.F. Genetic alterations in liver carcinogenesis. Crit. Rev. Oncog. 2000, 11:19-62.
4. Bruix J., Boix L., Sala M., Llovet J.M. Focus on hepatocellular carcinoma. Cancer Cell 2004, 5:215-221.
5. McGlynn K.A., London W.T. Epidemiology and natural history of hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 2005, 19:3-23.
6. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:S27-S34.
7. Tanaka Y., Hanada K., Mizokami M., Yeo A.E., Shih J.W., Gojobori T., Alter H.J. Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15584-15589.
8. Taylor-Robinson S.D., Foster G.R., Arora S., Hargreaves S., Thomas H.C. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997, 350:1142-1143.
9. Sherman M. Modern approach to hepatocellular carcinoma. Curr. Gastroenterol. Rep. 2011, 13:49-55.
10. Calvisi D.F., Pascale R.M., Feo F. Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev. Recent Clin. Trials 2007, 2:217-236.
11. Frau M., Biasi F., Feo F., Pascale R.M. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol. Aspects Med. 2010, 31:179-193.
12. Kern M.A., Breuhahn K., Schirmacher P. Molecular pathogenesis of human hepatocellular carcinoma. Adv. Cancer Res. 2002, 86:67-112.
13. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., Llovet J.M. Genomics and signalling pathways in hepatocellular carcinoma. Semin. Liver Dis. 2007, 27:55-76.
14. Feo F., De Miglio M.R., Simile M.M., Muroni M.R., Calvisi D.F., Frau M., Pascale R.M. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim. Biophys. Acta 2006, 1765:126-147.
15. Farazi P.A., De Pinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
16. Imbeaud S., Ladeiro Y., Zucman-Rossi J. Identification of novel oncogenes and tumour suppressors in hepatocellular carcinoma. Semin. Liver Dis. 2010, 30:75-86.
17. Lee J.S., Grisham J.W., Thorgeirsson S.S. Comparative functional genomics for identifying models of human cancer. Carcinogenesis 2005, 26:1013-1020.
18. Hardell L., Bengtsson N.O., Jonsson U., Eriksson S., Larsson L.G. Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria-an epidemiological investigation. Br. J. Cancer 1984, 50:389-397.
19. Gisbert J.P., García-Buey L., Alonso A., Rubio S., Hernándezm A., Pajares J.M., García-Díez A., Moreno-Otero R. Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. Eur. J. Gastroenterol. Hepatol. 2004, 16:689-692.
20. Dürr R., Caselmann W.H. Carcinogenesis of primary liver malignancies. Langenbecks Arch. Surg. 2000, 385:154-161.
21. Limmer J., Fleig W.E., Leupold D., Bittner R., Ditschuneit H., Beger H.G. Hepatocellular carcinoma in type I glycogen storage disease. Hepatology 1988, 8:531-537.
22. Franco L.M., Krishnamurthy V., Bali D., Weinstein D.A., Arn P., Clary B., Boney A., Sullivan J., Frush D.P., Chen Y.T., Krishnani P.S. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J. Inherit. Metab. Dis. 2005, 28:153-162.
23. Labrune P., Trioche P., Duvaltier I., Chevalier P., Odievre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J. Pediatr. Gastroenterol. Nutr. 1997, 24:276-279.
24. Rake J.P., Visser G., Labrune P., Leonard J.V., Ullrich K., Smit G.P. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur. J. Pediatr. 2002, 161:S20-S34.
25. Elmberg M., Hultcrantz R., Ekbom A., Brandt L., Olsson S., Olsson R., Lindgren S., Lööf L., Stål P., Wallerstedt S., Almer S., Sandberg-Gertzén H., Askling J. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003, 125:1733-1741.
26. Mieles L.A., Esquivel C.O., Van Thiel D.H., Koneru B., Makowka L., Tzakis A.G., Starzl T.E. Liver transplantation for tyrosinemia. A review of 10 cases from the University of Pittsburgh. Dig. Dis. Sci. 1990, 35:153-157.
27. Wong R.J., Gish R., Frederick T., Bzowej N., Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig. Dis. Sci. 2011, 56:578-585.
28. El-Serag H.B., Hampel H., Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 2006, 4:369-380.
29. Hassan M.M., Kaseb A., Li D., Patt Y.Z., Vauthey J.N., Thomas M.B., Curley S.A., Spitz M.R., Sherman S.I., Abdalla E.K., Davila M., Lozano R.D., Hassan D.M., Chan W., Brown T.D., Abbruzzese J.L. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 2009, 49:1563-1570.
30. Ertle J., Dechêne A., Sowa J.P., Penndorf V., Herzer K., Kaiser G., Schlaak J.F., Gerken G., Syn W.K., Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 2011, 128:2436-2443.
31. Indulski J.A., Lutz W. Metabolic genotype in relation to individual susceptibility to environmental carcinogens. Int. Arch. Occup. Environ. Health 2000, 73:71-85.
32. Kato S., Tajiri T., Matsukura N., Matsuda N., Taniai N., Mamada H., Yoshida H., Kiyam T., Naito Z. Genetic polymorphisms of aldehyde dehydrogenase 2, cytochrome p450 2E1 for liver cancer risk in HCV antibody-positive Japanese patients and the variations of CYP2E1 mRNA expression levels in the liver due to its polymorphism. Scand. J. Gastroenterol. 2003, 38:886-893.
33. Agundez J.A., Olivera M., Ladero J.M., Rodriguez-Lescure A., Ledesma M.C., Diaz-Rubio M., Meyer U.A., Benitez J. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 1996, 6:501-512.
34. Hsieh L.L., Huang R.C., Yu M.W., Chen C.J., Liaw Y.F. L-myc, GST M1 genetic polymorphism and hepatocellular carcinoma risk among chronic hepatitis B carriers. Cancer Lett. 1996, 103:171-176.
35. Dragani T.A. Risk of HCC: genetic heterogeneity and complex genetics. J. Hepatol. 2010, 52:252-257.
36. Yu M.W., Chang H.C., Liaw Y.F., Lin S.M., Lee S.D., Liu C.J., Chen P.J., Hsiao T.J., Lee P.H., Chen C.J. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J. Natl. Cancer Inst. 2000, 92:1159-1164.
37. Cai R.L., Meng W., Lu H.Y., Lin W.Y., Jiang F., Shen F.M. Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China. World J. Gastroenterol. 2003, 9:2428-2432.
38. Fernandez E., La Vecchia C., D'Avanzo B., Negri E., Franceschi S. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 1994, 3:209-212.
39. Hemminki K., Li X. Familial risks of cancer as a guide to gene identification and mode of inheritance. Int. J. Cancer 2004, 110:291-294.
40. Shen F.M., Lee M.K., Gong H.M., Cai X.Q., King M.C. Complex segregation analysis of primary hepatocellular carcinoma in Chinese families: interaction of inherited susceptibility and hepatitis B viral infection. Am. J. Hum. Genet. 1991, 49:88-93.
41. Manenti G., Galvan A., Falvella F.S., Pascale R.M., Spada E., Milani S., Gonzalez Neira A., Feo F., Dragani T.A. Genetic control of resistance to hepatocarcinogenesis by the mouse Hpcr3 locus. Hepatology 2008, 48:617-623.
42. Shih W.L., Yu M.W., Chen P.J., Yeh S.H., Lo M.T., Chang H.C., Liaw Y.F., Lin S.M., Liu C.J., Lee S.D., Lin C.L., Hsiao C.K., Yang S.Y., Chen C.J. Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area. Oncogene 2006, 25:3219-3224.
43. Shih W.L., Yu M.W., Chen P.J., Wu T.W., Lin C.L., Liu C.J., Lin S.M., Tai D.I., Lee S.D., Liaw Y.F. Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study. Eur. J. Hum. Genet. 2009, 1:1250-1259.
44. Kumar V., Kato N., Urabe Y., Takahashi A., Muroyama R., Hosono N., Otsuka M., Tateishi R., Omata M., Nakagawa H., Koike K., Kamatani N., Kubo M., Nakamura Y., Matsuda K. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat. Genet. 2011, 43:455-458.
45. Donato F., Gelatti U., Limina R.M., Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 2006, 25:3756-3770.
46. Feo F., Pascale R.M., Calvisi D.F. Models for liver cancer. The Cancer Handbook 2007, vol. 2:1118-1133. Wiley, New York. 2nd Edition. M.R. Alison (Ed.).
47. Newell P., Villanueva A., Friedman S.L., Koike K., Llovet J.M. Experimental models of hepatocellular carcinoma. J. Hepatol. 2008, 48:858-879.
48. Bralet M.P., Regimbeau J.M., Pineau P., Dubois S., Loas G., Degos F., Valla D., Belghiti J., Degott C., Terris B. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000, 32:200-204.
49. Simile M.M., De Miglio M.R., Muroni M.R., Frau M., Asara G., Serra S., Muntoni M.D., Seddaiu M.A., Daino L., Feo F., Pascale R.M. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Carcinogenesis 2004, 25:333-341.
50. De Miglio M.R., Simile M.M., Muroni M.R., Pusceddu S., Calvisi D.F., Carru A., Seddaiu M.A., Daino L., Deiana L., Pascale R.M., Feo F. c-myc overexpression and amplification correlate with progression of preneoplastic liver lesions to malignancy in the poorly susceptible Wistar rat strain. Mol. Carcinog. 1999, 25:21-29.
51. Kaposi-Novak P., Libbrecht L., Woo H.G., Lee Y.H., Sears N.C., Coulouarn C., Conner E.A., Factor V.M., Roskams T., Thorgeirsson S.S. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res. 2009, 69:2775-2782.
52. Takahashi Y., Kawate S., Watanabe M., Fukushima J., Mori S., Fukusato T. Amplification of c-myc and cyclin D1 genes in primary and metastatic carcinomas of the liver. Pathol. Int. 2007, 5:437-442.
53. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., Bachman M.H., Borowsky A.D., Ruebner B., Cardiff R.D., Yang Q., Bishop J.M., Contag C.H., Felsher D.W. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431:1112-1117.
54. Zhang Y.J., Jiang W., Chen C.J., Lee C.S., Kahn S.M., Santella R.M., Weinstein I.B. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 1993, 196:1010-1016.
55. Ohashi R., Gao C., Miyazaki M., Hamazaki K., Tsuji T., Inoue Y., Uemura T., Hirai R., Shimizu N., Namba M. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinoma. Anticancer Res. 2001, 21:657-662.
56. Pascale R.M., Simile M.M., De Miglio M.R., Muroni M.R., Calvisi D.F., Asara G., Casabona D., Frau M., Seddaiu M.A., Feo F. Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis. Hepatology 2002, 35:1341-1350.
57. Adams P.D. Regulation of retinoblastoma tumour suppressor protein by cyclin/cdks. Biochim. Biophys. Acta 2001, 1471:123-133.
58. Qin L.X., Tang Z.Y. The prognostic molecular markers in hepatocellular carcinoma. World J. Gastroenterol. 2002, 8:385-392.
59. Matsuda Y. Molecular mechanism underlying the functional loss of cyclin-dependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. World J. Gastroenterol. 2008, 14:1734-1740.
60. Stepanova L., Leng X., Parker S.B., Harper J.W. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 1996, 10:1491-1502.
61. Gaubatz S., Lees J.A., Lindeman G.J., Livingston D.M. E2F4 is exported from the nucleus in a CRM1-dependent manner. Mol. Cell. Biol. 2001, 21:1384-1392.
62. Crosby M.E., Almasan A. Opposing roles of E2Fs in cell proliferation and death. Cancer Biol. Ther. 2004, 3:1208-1211.
63. Pascale R.M., Simile M.M., Calvisi D.F., Frau M., Muroni M.R., Seddaiu M.A., Daino L., Muntoni M.D., De Miglio M.R., Thorgeirsson S.S., Feo F. Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology 2005, 42:1310-1319.
64. Calvisi D.F., Pinna F., Ladu S., Muroni M.R., Frau M., Demartis I., Tomasi M.L., Sini M., Simile M.M., Seddaiu M.A., Feo F., Pascale R.M. The degradation of cell cycle regulators by SKP2/CKS1 ubiquitin ligase is genetically controlled in rodent liver cancer and contributes to determine the susceptibility to the disease. Int. J. Cancer 2010, 126:1275-1281.
65. Calvisi D.F., Ladu S., Pinna F., Frau M., Tomasi M.L., Sini M., Simile M.M., Bonelli P., Muroni M.R., Seddaiu M.A., Lim D.S., Feo F., Pascale R.M. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 2009, 137:1816-1826.
66. Rodier G., Coulombe P., Tanguay P.L., Boutonnet C., Meloche S. Phosphorylation of Skp2 regulated by CDK2 and Cdc14B protects it from degradation by APC(Cdh1) in G1 phase. EMBO J. 2008, 27:679-691.
67. Wierstra, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol. Chem. 2007, 388:1257-1274.
68. Calvisi D.F., Pinna F., Ladu S., Pellegrino R., Simile M.M., Frau M., De Miglio M.R., Tomasi M.L., Sanna V., Muroni M.R., Feo F., Pascale R.M. Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut 2009, 58:679-687.
69. Wang I.C., Chen Y.J., Hughes D., Petrovic V., Major M.L., Park H.J., Tan Y., Ackerson T., Costa R.H. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell. Biol. 2005, 25:10875-10894.
70. Schiffer E., Housset C., Cacheux W., Wendum D., Desbois-Mouthon C., Rey C., Clergue F., Poupon R., Barbu V., Rosmorduc O. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005, 41:307-314.
71. Berasain C., Perugorria M.J., Latasa M.U., Castillo J., Goñi S., Santamaría M., Prieto J., Avila M.A. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp. Biol. Med. (Maywood) 2009, 234:713-725.
72. Cariani E., Lasserre C., Seurin D., Hamelin B., Kemeny F., Franco D., Czech M.P., Ullrich A., Brechot C. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumours, and liver cirrhosis. Cancer Res. 1988, 48:6844-6849.
73. Desbois-Mouthon C., Cacheux W., Blivet-Van Eggelpoel M.J., Barbu V., Fartoux L., Poupon R., Housset C., Rosmorduc O. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int. J. Cancer 2006, 119:2557-2566.
74. Chen L., Shi Y., Jiang C.Y., Wei L.X., Lv Y.L., Wang Y.L., Dai G.H. Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma. Int. J. Biol. Markers 2011, 26:108-116.
75. Tavian D., De Petro P.G., Benetti A., Portolani N., Giulini S.M., Barlati S. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int. J. Cancer 2000, 87:644-649.
76. Kaposi-Novak P., Lee J.S., Gomez-Quiroz L., Coulouarn C., Factor V.M., Thorgeirsson S.S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 2006, 116:1582-1595.
77. Chung Y.H., Kim J.A., Song B.C., Lee G.C., Koh M.S., Lee Y.S., Lee S.G., Suh D.J. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 2000, 89:977-982.
78. Berasain C., Castillo J., Perugorria M.J., Prieto J., Avila M.A. Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett. 2007, 254:30-41.
79. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
80. Marshall C. How do small GTPase signal transduction pathways regulate cell cycle entry?. Curr. Opin. Cell Biol. 1999, 11:732-736.
81. Pedersen P.L., Mathupala S., Rempel A., Geschwind J.F., Ko Y.H. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta 2002, 1555:14-20.
82. Baba M., Yamamoto R., Iishi H., Tatsuta M. Ha-ras mutations in N-nitrosomorpholine-induced lesions and inhibition of hepatocarcinogenesis by antisense sequences in rat liver. Int. J. Cancer 1977, 72:815-820.
83. Weihrauch M., Benicke M., Lehnert G., Wittekind C., Wrbitzky R., Tannapfel A. Frequent k-ras-2 mutations and p16 (INK4A) methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br. J. Cancer 2001, 84:982-989.
84. Calvisi D.F., Pinna F., Ladu S., Pellegrino R., Sanna V., Sini M., Daino L., Simile M.M., De Miglio M.R., Frau M., Tomasi M.L., Seddaiu M.A., Muroni M.R., Feo F., Pascale R.M. Ras-driven proliferation and apoptosis signalling during rat liver carcinogenesis is under genetic control. Int. J. Cancer 2008, 23:2057-2064.
85. Calvisi D.F., Pinna F., Meloni F., Ladu S., Pellegrino R., Sini L., Daino L., Simile M.M., De Miglio M.R., Virdis P., Frau M., Tomasi M.L., Seddaiu M.A., Muroni M.R., Feo F., Pascale R.M. Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated-kinase-mediated control of growth in human hepatocellular carcinoma. Cancer Res. 2008, 68:4192-4200.
86. Schmitz K.J., Wohlschlaeger J., Lang H., Sotiropoulos G.C., Malago M., Steveling K., Reis H., Cicinnati V.R., Schmid K.W., Baba H.A. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J. Hepatol. 2008, 48:83-90.
87. Panteva M., Korkaya H., Jameel S. Hepatitis viruses and the MAPK pathway: is this a survival strategy?. Virus Res. 2003, 92:131-140.
88. Arbuthnot P., Capovilla A., Kew M. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J. Gastroenterol. Hepatol. 2000, 15:357-368.
89. Mandrekar P., Szabo G. Signalling pathways in alcohol-induced liver inflammation. J. Hepatol. 2009, 50:1258-1266.
90. Lin Y.W., Yang J.L. Cooperation of ERK and SCFSkp2 for MKP-1 destruction provides a positive feedback regulation of proliferating signalling. J. Biol. Chem. 2006, 281:915-926.
91. Franke T.F. PI3K/Akt: getting it right matter. Oncogene 2008, 27:6473-6488.
92. Boyault S., Rickman D.S., de Reyniès A., Balabaud C., Rebouissou S., Jeannot E., Hérault A., Saric J., Belghiti J., Franco D., Bioulac-Sage P., Laurent-Puig P., Zucman-Rossi J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52.
93. Alexia C., Fallot G., Lasfer M., Schweizer-Groyer G., Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem. Pharmacol. 2004, 68:1003-1015.
94. Carlin C.R., Simon D., Mattison J., Knowles B.B. Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines. Mol. Cell. Biol. 1988, 8:25-34.
95. Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J., Lee S.H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480.
96. Feitelson M.A., Pan J., Lian Z. Early molecular and genetic determinants of primary liver malignancy. Surg. Clin. North Am. 2004, 84:339-354.
97. Hu T.H., Huang C.C., Lin P.R., Chang H.W., Ger L.P., Lin Y.W., et al. Expression and prognostic role of tumour suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003, 97:1929-1940.
98. Nakanishi K., Sakamoto M., Yamasaki S., Todo S., Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005, 103:307-312.
99. Villanueva A., Chiang D.Y., Newell P., Peix J., Thung S., Alsinet C., Tovar V., Roayaie S., Minguez B., Sole M., Battiston C., Van Laarhoven S., Fiel M.I., Di Feo A., Hoshida Y., Yea S., Toffanin S., Ramos A., Martignetti J.A., Mazzaferro V., Bruix J., Waxman S., Schwartz M., Meyerson M., Friedman S.L., Llovet J.M. Pivotal role of mTOR signalling in hepatocellular carcinoma. Gastroenterology 2008, 135:1972-1983.
100. Nakanishi K., Sakamoto M., Yasuda J., Takamura M., Fujita N., Tsuruo T., Todo S., Hirohashi S. Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorageindependent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res. 2002, 62:2971-2975.
101. Sahin F., Kannangai R., Adegbola O., Wang J., Su G., Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin. Cancer Res. 2004, 10:8421-8425.
102. Rizell M., Andersson M., Cahlin C., Hafström L., Olausson M., Lindnér P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int. J. Clin. Oncol. 2008, 13:66-70.
103. Parekh P., Rao K.V. Overexpression of cyclin D1 is associated with elevated levels of MAP kinases, Akt and Pak1 during diethylnitrosamine-induced progressive liver carcinogenesis. Cell Biol. Int. 2007, 31:35-43.
104. Factor V., Oliver A.L., Panta G.R., Thorgeirsson S.S., Sonenshein G.E., Arsura M. Roles of Akt/PKB and IKK complex in constitutive induction of NF-kappaB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice. Hepatology 2001, 34:32-41.
105. Datta J., Majumder S., Kutay H., Motiwala T., Frankel W., Costa R., Cha H.C., MacDougald O.A., Jacob S.T., Ghoshal K. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signalling cascade. Cancer Res. 2007, 67:2736-2746.
106. Peyrou M., Bourgoin L., Foti M. PTEN in liver diseases and cancer. World J. Gastroenterol. 2010, 16:4627-4633.
107. Frau M., Ladu S., Calvisi D.F., Simile M.M., Bonelli P., Daino L., Tomasi M.L., Seddaiu M.A., Feo F., Pascale R.M. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype. J. Hepatol. 2011, 55:111-119.
108. Calvisi D.F., Simile M.M., Ladu S., Frau M., Tomasi M.L., Demartis M.I., Daino L., Seddaiu M.A., Brozzetti S., Feo F., Pascale R.M. Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53. Hepatology 2011, 53:1226-1236.
109. Xu Y., Qu X., Zhang X., Luo Y., Zhang Y., Luo Y., Hou K., Liu Y. Midkine positively regulates the proliferation of human gastric cancer cells. Cancer Lett. 2009, 279:137-144.
110. Xiao L., Gong L.L., Yuan D., Deng M., Zeng X.M., Chen L.L., Zhang L., Yan Q., Liu J.P., Hu X.H., Sun S.M., Liu J., Ma H.L., Zheng C.B., Fu H., Chen P.C., Zhao J.Q., Xie S.S., Zou L.J., Xiao Y.M., Liu W.B., Zhang J., Liu Y., Li D.W. Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation. Cell Death Differ. 2010, 17:1448-1462.
111. Wu G., Morris S.M. Arginine metabolism: nitric oxide and beyond. Biochem. J. 1998, 1336:1-17.
112. Arsura M., Cavin L.G. Nuclear factor-kB and liver carcinogenesis. Cancer Lett. 2005, 229:157-169.
113. Pascale R.M., Frau M., Feo F. Prognostic significance of iNOS in hepatocellular carcinoma. Nitric Oxide (NO) and Cancer 2010, 309-328. Springer, New York, ch. 17. B. Bonavida (Ed.).
114. Calvisi D.F., Pinna F., Ladu S., Pellegrino R., Muroni M.R., Simile M.M., De Miglio M.R., Frau M., Tomasi M.L., Seddaiu M.A., Daino L., Virdis P., Feo F., Pascale R.M. Aberrant iNOS signalling is under genetic control in rodent liver cancer and potentially prognostic for human disease. Carcinogenesis 2008, 29:1639-1647.
115. Derynck R., Akhurst R.J., Balmain A. TGF-beta signalling in tumour suppression and cancer progression. Nat. Genet. 2001, 29:117-129.
116. Glasgow E., Mishra L. Transforming growth factor-β signalling and ubiquitinators in cancer. Endocr. Relat. Cancer 2008, 15:59-71.
117. Tang B., Bottinger E.P., Jakowlew S.B., Bagnall K.M., Mariano J., Anver M.R., Letterio J.J., Wakefield L.M. Transforming growth factor-beta1 is a new form of tumour suppressor with true haploid insufficiency. Nat. Med. 1998, 4:802-807.
118. Santoni-Rugiu E., Jensen M.R., Factor V.M., Thorgeirsson S.S. Acceleration of c-myc-induced hepatocarcinogenesis by co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signalling disruption. Am. J. Pathol. 1999, 154:1693-1700.
119. Im Y.H., Kim H.T., Kim I.Y., Factor V.M., Hahm K.B., Anzano M., Jang J.J., Flanders K., Haines D.C., Thorgeirsson S.S., Sizeland A., Kim S.J. Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. Cancer Res. 2001, 61:6665-6668.
120. Ikegami T. Transforming growth factor-beta signalling and liver cancer stem cell. Hepatol. Res. 2009, 39:847-849.
121. Baek H.J., Pishvaian M.J., Tang Y., Kim T.H., Yang S., Zouhairi M.E., Mendelson J., Shetty K., Kallakury B., Berry D.L., Shin K.H., Mishra B., Reddy E.P., Kim S.S., Mishra L. Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer. Hepatology 2011, 53:1676-1684.
122. Idobe Y., Murawaki Y., Kitamura Y., Kawasaki H. Expression of transforming growth factor-beta 1 in hepatocellular carcinoma in comparison with the non-tumour tissue. Hepatogastroenterology 2003, 50:54-59.
123. Song B.C., Chung Y.H., Kim J.A., Choi W.B., Suh D.D., Pyo S.I., Shin J.W., Lee H.C., Lee Y.S., Suh D.J. Transforming growth factor beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002, 94:175-180.
124. Fransvea E., Mazzocca A., Antonaci S., Giannelli G. Targeting transforming growth factor (TGF)-beta RI inhibits activation of beta 1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 2009, 49:839-850.
125. Song B.C., Chung Y.H., Kim J.A., Choi W.B., Suh D.D., Pyo S.I., Shin J.W., Lee H.C., Lee Y.S., Suh D.J. Transforming growth factor beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002, 94:175-180.
126. van Zijl F., Zulehner G., Petz M., Schneller D., Kornauth C., Hau M., Machat G., Grubinger M., Huber H., Mikulits W. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol. 2009, 5:1169-1179.
127. Pan X., Wang X., Lei W., Min L., Yang Y., Wang X., Song J. Nitric oxide suppresses transforming growth factor-beta1-induced epithelial-to-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 2009, 50:1577-1587.
128. Giannelli G., Mazzocca A., Fransvea E., Lahn M., Antonaci S. Inhibiting TGF-β signalling in hepatocellular carcinoma. Biochim. Biophys. Acta 2011, 1815:214-223.
129. Ueno T., Hashimoto O., Kimura R., Torimura T., Kawaguchi T., Nakamura T., Sakata R., Koga H., Sat M.D. Relation of type II transforming growth factor-beta receptor to hepatic fibrosis and hepatocellular carcinoma. Int. J. Oncol. 2001, 18:49-55.
130. Park Y., Lee C.H., Sol M.Y., Suh K.S., Yoon S.Y., Kim J.W. Expression and localization of the transforming growth factor-type I receptor and Smads in preneoplastic lesions during chemical hepatocarcinogenesis in rats. J. Korean Med. Sci. 2003, 18:510-519.
131. Park Y.N., Chae K.J., Oh B.K., Choi J., Choi K.S., Park C. Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-beta. Hepatogastroenterology 2004, 51:396-400.
132. Yakicier M.C., Irmak M.B., Romano A., Kew M., Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999, 18:4879-4883.
133. Yuan F., Zhou W., Zou C., Zhang Z., Hu H., Dai Z., Zhang Y. Expression of Oct4 in HCC and modulation to wnt/β-catenin and TGF-β signal pathways. Mol. Cell. Biochem. 2010, 343:155-162.
134. Mishra L., Derynck R., Mishra B. Transforming growth factor-beta signalling in stem cells and cancer. Science 2005, 310:68-71.
135. Papageorgis P., Cheng K., Ozturk S., Gong Y., Lambert A.W., Abdolmaleky H.M., Zhou J.R., Thiagalingam S. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res. 2011, 71:998-1008.
136. Androutsellis-Theotokis, Leker R.R., Soldner F., Hoeppner D.J., Ravin R., Poser S.W., Rueger M.A., Bae S.K., Kittappa R., McKay R.D. Notch signalling regulates stem members in vivo and in vitro. Nature 2006, 442:823-826.
137. Bray S.J. Notch signalling: a simple pathway become complex. Nat. Rev. Mol. Cell Biol. 2006, 7:678-689.
138. Tien A.C., Rajan A., Bellen H.J. A Notch updated. J. Cell Biol. 2009, 184:621-629.
139. Davis R.L., Turner D.L. Vertebrate hairy and enhancer of split related proteins: transcriptional repressors regulating cellular differentiation and embryonic patterning. Oncogene 2001, 20:8342-8357.
140. Sahlgren C., Gustafsson M.V., Jin S., Poellinger L., Lendahl U. Notch signalling mediates hypoxia-induced tumour cell migration and invasion. Proc. Natl. Acad. Sci. U. S. A. 2008, 15:6392-6397.
141. Grego-Bessa J., Diez J., Timmerman L., de la Pompa J.L. Notch and epithelial-mesenchyme transition in development and tumour progression: another turn of the screw. Cell Cycle 2004, 3:718-721.
142. Christensen H.M., Lin B., Norton J. Linking Notch signalling, chromatin remodeling, and T-cell leukemogenesis. J. Cell. Biochem. Suppl. 2000, 35:46-53.
143. Stockhausen M.T., Sjolund J., Axelson H. Regulation of the Notch target gene Hes-1 by TGFa induced Ras/MAPK signalling in human neuroblastoma cells. Exp. Cell Res. 2005, 310:218-228.
144. Fitzgerald K., Harrington A., Leder P. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 2000, 19:4191-4198.
145. Cantarini M.C., de la Monte S.M., Pang M., Tong M., D'Errico A., Trevisani F., Wands J.R. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signalling mechanisms. Hepatology 2006, 44:446-457.
146. Gao J., Song Z., Chen Y., Xia L., Wang J., Fan R., Du R., Zhang F., Hong L., Song J., Zou X., Xu H., Zheng G., Liu J., Fan D. Deregulated expression of Notch receptors in human hepatocellular carcinoma. Dig. Liver Dis. 2008, 40:114-121.
147. Gramantieri L., Giovannini C., Lanzi A., Chieco P., Ravaioli M., Venturi A., Grazi G.L., Bolondi L. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int. 2007, 27:997-1007.
148. Wang F., Zhou H., Xia X., Sun Q., Wang Y., Cheng B. Activated Notch signalling is required for hepatitis B virus X protein to promote proliferation and survival of human hepatic cells. Cancer Lett. 2010, 298:64-73.
149. Qi R., An H., Yu Y., Zhang M., Liu S., Xu H., Guo Z., Cheng T., Cao X. Notch1 signalling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res. 2003, 63:8323-8832.
150. Wang C., Qi R., Li N., Wang Z., An H., Zhang Q., Yu Y., Cao X. Notch1 signalling sensitizes tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression. J. Biol. Chem. 2009, 284:16183-16190.
151. Chappell W.H., Green T.D., Spengeman J.D., McCubrey J.A., Akula S.M., Bertrand F.E. Increased protein expression of the PTEN tumour suppressor in the presence of constitutively active Notch-1. Cell Cycle 2005, 4:1389-1395.
152. Lim S.O., Park Y.M., Kim H.S., Quan X., Yoo J.E., Park Y.N., Choi G.H., Jung G. Notch1 differentially regulates oncogenesis by wild type p53 overexpression and p53 mutation in grade III hepatocellular carcinoma. Hepatology 2011, 53:1352-1362.
153. Oishi N., Wang X.W. Novel therapeutic strategies for targeting liver cancer stem cells. Int. J. Biol. Sci. 2011, 7:517-535.
154. Cao L., Zhou Y., Zhai B., Liao J., Xu W., Zhang R., Li J., Zhang Y., Chen L., Qian H., Wu M., Yin Z. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011, 11:71.
155. Song W., Li H., Tao K., Li R., Song Z., Zhao Q., Zhang F., Dou K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int. J. Clin. Pract. 2008, 62:1212-1218.
156. Yeh C.T., Kuo C.J., Lai M.W., Chen T.C., Lin C.Y., Yeh T.S., Lee W.C. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer 2009, 9:324.
157. Sasaki, Kamiyama T., Yokoo H., Nakanishi K., Kubota K., Haga H., Matsushita M., Ozaki M., Matsuno Y., Todo S. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol. Rep. 2010, 24:537-546.
158. Zhu Z., Hao X., Yan M., Yao M., Ge C., Gu J., Li J. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int. J. Cancer 2010, 126:2067-2078.
159. Ruiz A.A.I., Sanchez P., Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat. Rev. Cancer 2002, 2:361-372.
160. Pasca di Magliano M., Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat. Rev. Cancer 2003, 3:903-911.
161. Kasper M., Regl G., Frischauf A.M., Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur. J. Cancer 2006, 42:437-445.
162. Yang L., Xie G., Fan Q., Xie J. Activation of the hedgehog-signalling pathway in human cancer and the clinical implications. Oncogene 2010, 29:469-481.
163. Vanessa Ribes V., Briscoe J. Establishing and interpreting graded sonic hedgehog signalling during vertebrate neural tube patterning: the role of negative feedback. Cold Spring Harb. Perspect. Biol. 2009, 1:a002014.
164. Ruiz A.A.I., Palma V., Dahmane N. Hedgehog-Gli signalling and the growth of the brain. Nat. Rev. Neurosci. 2002, 3:24-33.
165. Sicklick J.K., Li Y.X., Jayaraman A., Kannangai R., Qi Y., Vivekanandan P., Ludlow J.W., Owzar K., Chen W., Torbenson M.S., Diehl A.M. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006, 27:748-757.
166. Huang S., He J., Zhang X., Bian Y., Yang L., Xie G., Zhang K., Tang W., Stelter A.A., Wang Q., Zhang H., Xie J. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 2006, 27:1334-1340.
167. Patil M.A., Zhang J., Ho C., Cheung S.T., Fan S.T., Chen X. Hedgehog signalling in human hepatocellular carcinoma. Cancer Biol. Ther. 2006, 5:111-117.
168. Kim Y., Yoon J.W., Xiao X., Dean N.M., Monia B.P., Marcusson E.G. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res. 2007, 67:3583-3593.
169. Cheng W.T., Xu K., Tian D., Zhang Z.G., Liu L.J., Chen Y. Role of Hedgehog signalling pathway in proliferation and invasiveness of hepatocellular carcinoma cells. Int. J. Oncol. 2009, 34:829-836.
170. Chen X.L., Cheng Q.Y., She M.R., Wang Q., Huang X.H., Cao L.Q., Fu X., Chen J.S. Expression of sonic hedgehog signalling components in hepatocellular carcinoma and cyclopamine-induced apoptosis through Bcl-2 downregulation in vitro. Arch. Med. Res. 2010, 41:315-323.
171. Pereira T., Witek R.P., Syn W.K., Choi S.S., Bradrick S., Karaca G.F., Agboola K.M., Jung Y., Omenetti A., Moylan C.A., Yang L., Fernandez-Zapico M.E., Jhaveri R., Shah V.H., Pereira F.E., Diehl A.M. Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab. Invest. 2010, 90:1690-1703.
172. Riobo N.A., Haines G.M., Emerson C.P. Protein kinase C-delta and mitogen-activated protein/extracellular signal-regulated kinase-1 control GLI activation in hedgehog signalling. Cancer Res. 2006, 66:839-845.
173. Xie J., Aszterbaum M., Zhang X., Bonifas J.M., Zachary C., Epstein E., McCormick F. A role of PDGFRalpha in basal cell carcinoma proliferation. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:9255-9259.
174. Lin M., Guo L.M., Liu H., Du J., Yang J., Zhang L.J., Zhang B. Nuclear accumulation of glioma-associated oncogene 2 protein and enhanced expression of forkhead-box transcription factor M1 protein in human hepatocellular carcinoma. Histol. Histopathol. 2010, 25:1269-1275.
175. Kise Y., Takenaka K., Tezuka T., Yamamoto T., Miki H. Fused kinase is stabilized by Cdc37/Hsp90 and enhances Gli protein levels. Biochem. Biophys. Res. Commun. 2006, 351:78-84.
176. de La Coste, Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., Fabre M., Chelly J., Beldjord C., Kahn A., Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. U. S. A. 1998, 85:8847-8851.
177. Clevers H., Van de Wetering M. TCF/LEF factors earns their wings. Trends Genet. 1997, 13:485-489.
178. Polakis P. The oncogenic activation of beta-catenin. Curr. Opin. Genet. Dev. 1999, 9:15-21.
179. Laurent-Puig P., Legoix P., Bluteau O., Belghiti J., Franco D., Binot F., Monges G., Thomas G., Bioulac-Sage P., Zucman-Rossi J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001, 120:1763-1773.
180. Calvisi D.F., Factor V.M., Ladu S., Conner E.A., Thorgeirsson S.S. Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology 2004, 126:1374-1386.
181. Calvisi D.F., Thorgeirsson S.S. Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol. Pathol. 2005, 33:181-184.
182. Legoix P., Bluteau O., Bayer J., Perret C., Balabaud C., Belghiti J., Franco D., Thomas G., Laurent-Puig P., Zucman-Rossi J. β-Catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999, 18:4044-4046.
183. Hsu H.C., Jeng Y.M., Mao T.L., Chu J.S., Lai P.L., Peng S.Y. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am. J. Pathol. 2000, 157:763-770.
184. Liu L., Zhu X.D., Wang W.Q., Shen Y., Qin Y., Ren Z.G., Sun H.C., Tang Z.Y. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin. Cancer Res. 2010, 16:2740-2750.
185. Yamashita T., Forgues M., Wang W., Kim J.W., Ye Q., Jia H., Budhu A., Zanetti K.A., Chen Y., Qin L.X., Tang Z.Y., Wang X.W. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008, 68:1451-1456.
186. Fernandez-L, Kenney A.M. The Hippo in the room: a new look at a key pathway in cell growth and transformation. Cell Cycle 2010, 9:2292-2299.
187. Halder G., Johnson R.L. Hippo signalling: growth control and beyond. Development 2011, 138:9-22.
188. Zhao B., Tumaneng K., Guan K.L. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat. Cell Biol. 2011, 13:877-883.
189. Oka T., Mazack V., Sudol M. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J. Biol. Chem. 2008, 283:27534-27546.
190. Hao Y., Chun A., Cheung K., Rashidi B., Yang X. Tumour suppressor LATS1 is a negative regulator of oncogene YAP. J. Biol. Chem. 2008, 283:5496-5509.
191. Zhao B., Li L., Tumaneng K., Wang C.Y., Guan K.L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFβ-TRCP. Genes Dev. 2010, 24:72-85.
192. Zeng Q., Hong W. The emerging role of the Hippo pathway in cell contact inhibition, organ size control, and cancer development in mammal. Cancer Cell 2008, 13:188-192.
193. Chan S.W., Lim C.J., Chen L., Chong Y.F., Huang C., Song H., Hong W. The Hippo pathway in biological control and cancer development. J. Cell. Physiol. 2011, 226:928-939.
194. Zhao B., Li L., Lei Q., Guan K.L. The Hippo-YAP pathway in organ size control and carcinogenesis: an updated version. Genes Dev. 2010, 24:862-874.
195. Zheng T., Wang J., Jiang H., Liu L.X. Hippo signalling in oval cells and hepatocarcinogenesis. Cancer Lett. 2011, 302:91-99. {upwards double arrow}.
196. Xu M.Z., Yao T.J., Lee N.P., Ng I.O., Chan Y.T., Zender L., Lowe S.W., Poon R.T., Luk J.M. Yes associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009, 115:4576-4585.
197. Zhou D., Conrad C., Xia F., Park J.S., Payer B., Yin Y., Lauwers G.Y., Thasler W., Lee J.T., Avruch J., Bardeesy N. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009, 16:425-438.
198. Kowalik M.A., Saliba C., Pibiri M., Perra A., Ledda-Columbano G.M., Sarotto I., Ghiso E., Giordano S., Columbano A. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology 2011, 53:2086-2096.
199. Liu A.M., Poon R.T., Luk J.M. MicroRNA-375 targets Hippo-signalling effector YAP in liver cancer and inhibits tumour properties. Biochem. Biophys. Res. Commun. 2010, 394:623-627.
200. Lee K.P., Lee J.H., Kim T.S., Kim T.H., Park H.D., Byun J.S., Kim M.C., Jeong W.I., Calvisi D.F., Kim J.M., Lim D.S. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8248-8253.
201. Lu L., Li Y., Kim S.M., Bossuyt W., Liu P., Qiu Q., Wang Y., Halder G., Finegold M.J., Lee J.S., Johnson R.L. Hippo signalling is a potent in vivo growth and tumour suppressor pathway in the mammalian liver. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1437-1442.
202. Matallanas D., Romano D., Yee K., Meissl K., Kucerova L., Piazzolla D., Baccarini D.M., Vass J.K., Kolch W., O'neill E. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumour suppressor protein. Mol. Cell 2007, 27:962-975.
203. Kim D., Shu S., Coppola M.D., Kaneko S., Yuan Z.Q., Cheng J.Q. Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1-Akt pathway. PLoS One 2010, 5:e9616.
204. Romano D., Matallanas D., Weitsman G., Preisinger C., Ng T., Kolch W. Proapoptotic kinase MST2 coordinates signalling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res. 2010, 70:1195-1203.
205. Jang S.W., Yang S.J., Srinivasan S., Ye K. Akt phosphorylates MstI and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation. J. Biol. Chem. 2007, 282:30836-30844.
206. Yuan Z., Kim D., Shu S., Wu J., Guo J., Xiao L., Kaneko S., Coppola D., Cheng J.Q. Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic signalling through phosphorylation of threonine 120. J. Biol. Chem. 2010, 285:3815-3824.
207. Urtasun R., Latasa M.U., Demartis M.I., Balzani S., Goñi S., Garcia-Irigoyen O., Elizalde M., Azcona M., Pascale R.M., Feo F., Bioulac-Sage P., Balabaud C., Muntané J., Prieto J., Berasain C., Avila M.A. Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology 2011, 54:2149-2158.
208. Yu J., Poulton J., Huang Y.C., Deng W.M. The Hippo pathway promotes Notch signalling in regulation of cell differentiation, proliferation, and oocyte polarity. PLoS One 2008, 3:e1761.
209. Hergovich B.A. Hemmings, TAZ-mediated crosstalk between Wnt and Hippo signalling. Dev. Cell 2010, 18:508-509.
210. Mauviel A., Nallet-Staub F., Varelas X. Integrating developmental signals: a Hippo in the (path)way. Oncogene 2012, 31:1743-1756.
211. Locasale J.W., Cantley L.C., Vander Heiden M.G. Cancer's insatiable appetite. Nat. Biotechnol. 2009, 27:916-917.
212. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
213. Warburg O., Posener K., Negelein E. Ueber den stoffwechsel der tumoren. Biochem. Z. 1924, 152:319-344.
214. Feo F., Canuto R.A., Garcea R. Acceptor control ratio of mitochondria. Factors affecting it in Morris hepatoma 5123 and Yoshida hepatoma AH-130. Eur. J. Cancer 1973, 9:203-214.
215. Terranova T., Feo F., Gravela E., Gabiel L. Die wirkung der 2-desoxyglucose auf den energetischen stoffwechsel und auf proteinsynthese von tumorzellen und normalzellen. Zeit. Krebs. 1964, 66:41-45.
216. Kim J.W., Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006, 66:8927-8930.
217. Lopez-Rios F., Sanchez-Arago M., Garcia-Garcia E., Ortega A.D., Berrendero J.R., Pozo-Rodriguez F., Lopez-Encuentra A., Ballestin C., Cuezva J.M. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res. 2007, 67:9013-9017.
218. Swietach P., Vaughan-Jones R.D., Harris A.L. Regulation of tumor pH and the role of carbonic anhydrase. Cancer Metastasis Rev. 2007, 2:299-310.
219. Fischer K., Hoffmann P., Voelkl S., Meidenbauer N., Ammer J., Edinger M., Gottfried E., Schwarz S., Rothe G., Hoves S., Renner K., Timischl B., Mackensen A., Kunz-Schughart L., Andreesen R., Krause S.W., Kreutz M. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007, 109:3812-3819.
220. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 2004, 4:891-899.
221. Bannasch P., Jahn U., Hacker H., Su Q., Hoffmann W., Pichlmayr R., Otto G. Focal hepatic glycogenosis. Int. J. Oncol. 1977, 10:261-268.
222. Corona G., De Lorenzo E., Elia C., Simula M.P., Avellini C., Baccarani U., Lupo F., Tiribelli C., Colombatti A., Toffoli G. Differential proteomic analysis of hepatocellular carcinoma. Int. J. Oncol. 2010, 36:93-99.
223. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H., Cinalli R.M., Alavi A., Rudin C.M., Thompson C.B. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64:3892-3899.
224. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
225. Fan Y., Dickman K.G., Zong W.X. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J. Biol. Chem. 2010, 285:7324-7333.
226. Robey R.B., Hay N. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 2009, 19:25-31.
227. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's achilles' heel. Cancer Cell 2008, 13:473-482.
228. Chen, Pore N., Behrooz A., Ismail-Beigi F., Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 2001, 276:9519-9525.
229. Mazurek S., Boschek C.B., Hugoc F., Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 2005, 15:300-308.
230. Tong K., Zhao F., Thompson C.B. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr. Opin. Genet. Dev. 2009, 19:32-37.
231. Khatri S., Yepiskoposyan H., Gallo C.A., Tandon P., Plas D.R. FOXO3a regulates glycolysis via transcriptional control of tumor suppressor TSC1. J. Biol. Chem. 2010, 285:15960-15965.
232. Kim J.W., Dang C.V. Multifaceted roles of glycolytic enzymes. Trends Biochem. Sci. 2005, 30:142-150.
233. Wise D.R., DeBerardinis R.J., Mancuso A., Sayed N., Zhang X.Y., Pfeiffer H.K., Nissim I., Daikhin E., Yudkoff M., McMahon S.B., Thompson C.B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18782-18787.
234. Hu W., Zhang C., Wu R., Sun Y., Levine A., Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7455-7460.
235. Kim J.W., Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006, 66:8927-8930.
236. Zhang J., Xie Z., Dong Y., Wang S., Liu C., Zou M.H. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. J. Biol. Chem. 2008, 283:27452-27461.
237. Viollet, Guigas B., Leclerc J., Hébrard S., Lantier L., Mounier R., Andreelli F., Foretz M. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf.) 2009, 196:81-98.
238. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9:563-575.
239. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2001, 11:85-95.
240. Kim C.J., Cho Y.G., Park J.Y., Kim T.Y., Lee J.H., Kim H.S., Lee J.W., Song Y.H., Nam S.W., Lee S.H., Yoo N.J., Lee J.Y., Park W.S. Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. Eur. J. Cancer 2004, 40:136-141.
241. Martínez-López N., Varela-Rey M., Fernández-Ramos D., Woodhoo A., Vázquez-Chantada M., Embade N., Espinosa-Hevia L., Bustamante F.J., Parada L.A., Rodriguez M.S., Lu S.C., Mato J.M., Martínez-Chantar M.L. Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis. Hepatology 2010, 52:1621-1631.
242. Lu S.C., Alvarez L., Huang Z.Z., Chen L., An W., Corrales F.J., Avila M.A., Kanel G., Mato J.M. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5560-5565.
243. Leary S.C., Cobine P.A., Kaufman B.A., Guercin G.H., Mattman A., Palaty J., Lockitch G., Winge D.R., Rustin P., Horvath R., Shoubridge E.A. The human cytochrome c oxidase assembly factors SCO1 and SCO2 have regulatory roles in the maintenance of cellular copper homeostasis. Cell Metab. 2007, 5:9-20.
244. Weber G., Kizaki H., Shiotani T., Tzeng D., Williams J.C. The molecular correlation concept of neoplasia: recent advances and new challenges. Adv. Exp. Med. Biol. May 22-24 1977, 92:89-116.
245. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.
246. Swinnen J.V., Brusselmans K., Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9:358-365.
247. Yahagi N., Shimano H., Hasegawa K., Ohashi K., Matsuzaka T., Najima Y., Sekiya M., Tomita S., Okazaki H., Tamura Y., Iizuka Y., Ohashi K., Nagai R., Ishibashi S., Kadowaki T., Makuuchi M., Ohnishi S., Osuga J., Yamada N. Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur. J. Cancer 2005, 41:1316-1322.
248. Calvisi D.F., Wang C., Ho C., Ladu S., Lee S.A., Mattu S., Destefanis G., Delogu S., Zimmermann A., Ericsson J., Brozzetti S., Staniscia T., Chen X., Dombrowski F., Evert M. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signalling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011, 140:1071-1083.
249. Yamashita T., Honda M., Takatori H., Nishino R., Minato H., Takamura H., Ohta T., Kaneko S. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J. Hepatol. 2009, 50:100-110.
250. Stauffer J.K., Scarzello A.J., Andersen J.B., De Kluyver R.L., Back T.C., Weiss J.M., Thorgeirsson S.S., Wiltrout R.H. Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumours. Cancer Res. 2011, 71:2718-2727.
251. Copeland D.H., Salmon W.D. The occurrence of neoplasms in the liver, lung, and other tissues of rats as results of prolonged choline deficiency. Am. J. Pathol. 1946, 22:1059-1079.
252. Goshal A.K., Farber E. Induction of liver cancer by a diet deficient of choline and methionine without added carcinogens. Carcinogenesis 1984, 5:1367-1370.
253. Shivapurkar M., Poirier L.A. Tissue levels of S-adenosylmethionine and S-adensylhocysteine in rats fed choline-deficient, aminoacid-defined diets for one to five weeks. Carcinogenesis 1983, 4:1051-1057.
254. Garcea R., Pascale R.M., Daino L., Frassetto S., Cozzolino P., Ruggio M.E., Vannini M.G., Gaspa L., Feo F. Variations in ornithine decarboxylase activity and S-adenosyl-l-methionine and S-methylthioadenosine contents during the development of diethylnitrosamine-induced liver hyperplastic nodules and hepatocellular carcinomas. Carcinogenesis 1987, 8:653-658.
255. Garcea R., Daino L., Pascale R.M., Simile M.M., Puddu M., Frassetto S., Cozzolino P., Seddaiu M.A., Gaspa L., Feo F. Inhibition of promotion and persistent nodule growth by S-adenosyl-L-methionine in rat liver carcinogenesis: role of remodeling and apoptosis. Cancer Res. 1989, 49:1850-1856.
256. Mato M., Corrales F.J., Lu S.C., Avila M.A. S-Adenosylmethionine: a control switch that regulates liver function. FASEB J. 2002, 16:15-26.
257. Finkelstein J.D. Methionine metabolism in mammals. J. Nutr. Biochem. 1990, 1:228-237.
258. Ramani K., Mato J.M., Lu S.C. Role of methionine adenosyltransferase genes in hepatocarcinogenesis. Cancers 2011, 3:1480-1497.
259. Calvisi D.F., Simile M.M., Ladu S., Pellegrino R., De Murtas V., Pinna F., Tomasi M.L., Frau M., Virdis P., De Miglio M.R., Muroni M.R., Pascale R.M., Feo F. Altered methionine metabolism and global DNA methylation in liver cancer: relationship with genomic instability and prognosis. Int. J. Cancer 2007, 121:2410-2420.
260. Finkelstein J.D. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. Clin. Chem. Lab. Med. 2007, 45:1694-1699.
261. Pascale R.M., Marras V., Simile M.M., Daino L., Pinna G., Bennati S., Carta M., Seddaiu M.A., Massarelli G., Feo F. Chemoprevention of rat liver carcinogenesis by S-adenosyl-L-methionine: a long-term study. Cancer Res. 1992, 52:4979-4986.
262. Pascale R.M., Simile M.M., De Miglio M.R., Nufris A., Daino L., Seddaiu M.A., Rao P.M., Rajalakshmi S., Sarma D.S.R., Feo F. Chemoprevention by S-adenosyl-L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid. Carcinogenesis 1995, 16:427-430.
263. Simile M.M., Saviozzi M., De Miglio M.R., Muroni M.R., Nufris A., Pascale R.M., Malvaldi G., Feo F. Persistent chemopreventive effect of S-adenosyl-L-methionine on the development of liver putative preneoplastic lesions induced by thiobenzamide in diethylnitrosamine-initiated rats. Carcinogenesis 1996, 17:1533-1537.
264. Lu S.C., Ramani K., Ou X., Lin M., Yu V., Ko K., Park R., Bottiglieri T., Tsukamoto H., Kanel G., French S.W., Mato J.M., Moats R., Grant E. S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. Hepatology 2009, 50:462-471.
265. Torres L., Avila M.A., Carretero M.V., Latasa M.U., Caballería J., López-Rodas G., Boukaba A., Lu S.C., Franco L., Mato J.M. Liver-specific methionine adenosyltransferase MAT1A gene expression is associated with a specific pattern of promoter methylation and histone acetylation: implications for MAT1A silencing during transformation. FASEB J. 2000, 14:95-102.
266. Tomasi M.L., Li T.W., Li M., Mato J.M., Lu S.C. Inhibition of human Methionine Adsenosyltransferase 1A transcription by coding region methylation. J. Cell. Physiol. 2012, 227:1583-1591.
267. Yang H., Huang Z.Z., Zeng Z., Chen C., Selby R.R., Lu S.C. Role of promoter methylation in increased methionine adenosyltransferase 2A expression in human liver cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 280:184-190.
268. M. Frau, M.L. Tomasi, M.M. Simile, M.I. Demartis, F. Salis, G. Latte, D.F. Calvisi, M.A. Seddaiu, L. Daino, C.F. Feo, S. Brozzetti, G. Solinas, S. Yamashita, T. Ushijima, F. Feo, R.M. Pascale, Role of transcriptional and post-transcriptional regulation of methionine adenosyltransferases in liver cancer progression. Hepatology, in press, doi:. doi:10.1002/hep.25643.
269. Brennan C.M., Steitz J.A. HuR and mRNA stability. Cell. Mol. Life Sci. 2001, 58:266-277.
270. Lal, Mazan-Mamczarz K., Kawai T., Yang X., Martindale J.L., Gorospe M. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J. 2004, 23:3092-3102.
271. Vázquez-Chantada M., Fernández-Ramos D., Embade N., Martínez-Lopez N., Varela-Rey M., Woodhoo A., Luka Z., Wagner C., Anglim P.P., Finnell R.H., Caballeria J., Laird-Offringa I.A., Gorospe M., Lu S.C., Mato J.M., Martinez-Chantar M.L. HuR/methyl-HuR and AUF1 regulate the MAT expressed during liver proliferation, differentiation, and carcinogenesis. Gastroenterology 2010, 138:1943-1953.
272. Eden, Gaudet F., Waghmare A., Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
273. Mann C.D., Neal C.P., Garcea G., Manson M.M., Dennison A.R., Berry D.P. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur. J. Cancer 2007, 43:979-992.
274. Martinez-Chantar M.L., Corrales F.J., Martinez-Cruz L.A., Garcia-Trevijano E.R., Huang Z.Z., Chen L., Kanel G., Avila M.A., Mato J.M., Lu S.C. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J. 2002, 16:1292-1294.
275. Tomasi M.L., Iglesias-Ara A., Yang H., Ramani K., Feo F., Pascale M.R., Martinez-Chantar M.L., Mato J.M., Lu S.C. S-adenosylmethionine regulates apurinic/apyrimidinic endonuclease 1 stability: implication in hepatocarcinogenesis. Gastroenterology 2009, 136:1025-1036.
276. Mol C.D., Hosfield D.J., Tainer J.A. Abasic site recognition by two apurinic/apyrimidinic endonuclease families in DNA base excision repair: the 3' ends justify the means. Mutat. Res. 2000, 460:211-229.
277. Tomasi M.L., Ramani K., Lopitz-Otsoa F., Rodriguez M.S., Li T.W., Ko K., Yang H., Bardag-Gorce F., Iglesias-Ara A., Feo F., Pascale R.M., Mato J.M., Lu S.C. S-adenosylmethionine regulates dual-specificity mitogen-activated protein kinase phosphatase 21 expression in mouse and human hepatocytes. Hepatology 2010, 51:2152-2161.
278. Li J., Ramani K., Sun Z., Zee C., Grant E.G., Yang H., Xia M., Oh P., Ko K., Mato J.M., Lu S.C. Forced expression of methionine adenosyltransferase 1A in human hepatoma cells suppresses in vivo tumorigenicity in mice. Am. J. Pathol. 2010, 176:2456-2466.
279. Majano P.L., García-Monzón C., García-Trevijano E.R., Corrales F.J., Cámara J., Ortiz P., Mato J.M., Avila M.A., Moreno-Otero R. S-Adenosylmethionine modulates inducible nitric oxide synthase gene expression in rat liver and isolated hepatocytes. J. Hepatol. 2001, 35:692-699.
280. García-Román R., Salazar-González D., Rosas S., Arellanes-Robledo J., Beltrán-Ramírez O., Fattel-Fazenda S., Villa-Treviño S. The differential NF-kB modulation by S-adenosyl-L-methionine, N-acetylcysteine and quercetin on the promotion stage of chemical hepatocarcinogenesis. Free Radic. Res. 2008, 42:331-343.
281. Zhao J., Dong L., Lu B., Wu G., Xu D., Chen J., Li K., Tong X., Dai J., Yao S., Wu M., Guo Y. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008, 135:956-968.
282. Kim J.W., Wang X.W. Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases?. Carcinogenesis 2003, 24:363-369.
283. Lee J.S., Thorgeirsson S.S. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004, 127:S51-S55.
284. Zhang L.H., Ji J.F. Molecular profiling of hepatocellular carcinomas by cDNA microarray. World J. Gastroenterol. 2005, 11:463-468.
285. Lee J.S., Thorgeirsson S.S. Comparative and integrative functional genomics of HCC. Oncogene 2005, 25:3801-3809.
286. Thorgeirsson S.S., Lee J.S., Grisham J.W. Molecular prognostication of liver cancer: end of the beginning. J. Hepatol. 2006, 44:798-805.
287. Andrisani O.M., Studach L.O., Merle P. Gene signatures in hepatocellular carcinoma (HCC). Semin. Cancer Biol. 2001, 21:4-9.
288. Maass T., Sfakianakis I., Staib F., Krupp M., Galle P.R., Teufel A. Micraarray-based gene expression analysis of hepatocellular carcinoma. Curr. Genomics 2010, 11:261-268.
289. Ellwood-Yen K., Graeber T.G., Wongvipat J., Iruela-Arispe M.L., Zhang J., Matusik R., Thomas G.V., Sawyers C.L. Myc-driven murine prostate cancer shares molecular features with human prostate tumours. Cancer Cell 2003, 4:223-238.
290. Sweet-Cordero, Mukherjee S., Subramanian A., You H., Roix J.J., Ladd-Acosta C., Mesirov J., Golub T.R., Jacks T. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat. Genet. 2005, 37:48-55.
291. Lee J.S., Chu I.S., Heo J., Calvisi D.F., Sun Z., Roskams T., Durnez A., Demetris A.J., Thorgeirsson S.S. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40:667-676.
292. Lee J.S., Chu I.S., Mikaelyan A., Calvisi D.F., Heo J., Reddy J.K., Thorgeirsson S.S. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat. Genet. 2004, 36:1306-1311.
293. Kimura M. Evolutionary rate at the molecular level. Nature 1968, 217:624-626.
294. King J.L., Jukes T.H. Non-Darwinian evolution. Science 1969, 164:788-798.
295. Lee J.S., Heo J., Libbrecht L., Chu I.S., Kaposi-Novak P., Calvisi D.F., Mikaelyan A., Roberts L.R., Demetris A.J., Sun Z., Nevens F., Roskams T., Thorgeirsson S.S. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 2006, 12:410-416.
296. Boyault S., Rickman D.S., de Reynies A., Balabaud C., Rebouissou S., Jeannot E., Hérault A., Saric J., Belghiti J., Franco D., Bioulac-Sage P., Laurent-Puig P., Zucman-Rossi J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52.
297. Andersen J.B., Loi R., Perra A., Factor V.M., Ledda-Columbano G.M., Columbano A., Thorgeirsson S.S. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology 2011, 51:1401-1409.
298. Solt D.B., Medline A., Farber E. Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis. Am. J. Pathol. 1997, 88:595-618.
299. M. Frau, M.M. Simile, M.L. Tomasi, M.I. Demartis, L. Daino, M.A. Seddaiu, S. Brozzetti, C.F. Feo, G. Massarelli, G. Solinas, F. Feo, J.S. Lee, R.M. Pascale, An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis, Cell. Oncol., in press.
300. Kaposi-Novak P., Lee J.S., Gòmez-Quiroz L., Coulouarn C., Factor V.M., Thorgeirsson S.S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 2006, 116:1582-1595.
301. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., Gupta S., Moore J., Wrobel M.J., Lerner J., Reich M., Chan J.A., Glickman J.N., Ikeda K., Hashimoto M., Watanabe G., Daidone M.G., Roayaie S., Schwartz M., Thung S., Salvesen H.B., Gabriel S., Mazzaferro V., Bruix J., Friedman S.L., Kumada H., Llovet J.M., Golub T.R. Gene expression in fixed tissues and outcome in hepatocellular carcinom. N. Engl. J. Med. 2008, 359:1995-2004.
302. Nam S.W., Park J.Y., Ramasamy A., Shevade S., Islam A., Long P.M., Park C.K., Park S.E., Kim S.Y., Lee S.H., Park W.S., Yoo N.J., Liu E.T., Miller L.D., Lee J.Y. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 2005, 42:809-818.
303. Llovet J.M., Chen Y., Wurmbach E., Roayaie S., Fiel M.I., Schwartz M., Thung S.N., Khitrov G., Zhang W., Villanueva A., Battiston C., Mazzaferro V., Bruix J., Waxman S., Friedman S.L. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006, 131:1758-1767.
304. Kaposi-Novak P., Libbrecht L., Woo H.G., Lee Y.H., Sears N.C., Coulouarn C., Conner E.A., Factor V.M., Roskams T., Thorgeirsson S.S. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res. 2009, 69:2775-2782.
305. Law P.T.-Y., Wong N. Emerging roles of microRNA in the intracellular signalling networks of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2011, 26:437-450.
306. Braconi C., Henry J.C., Kogure T., Schmittgen T., Patel T. The role of microRNAs in human liver cancers. Semin. Oncol. 2011, 38:752-763.
307. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
308. Kumar MicroRNA in HCV infection and liver cancer. Biochim. Biophys. Acta 2011, 1809:694-699.
309. Huang S., He X. The role of microRNAs in liver cancer progression. Br. J. Cancer 2011, 104:235-240.
310. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
311. Wu J.F., Shen W., Liu N.Z., Zeng G.L., Yang M., Zuo G.Q., Gan X.N., Ren H., Tang K.F. Down-regulation of dicer in hepatocellular carcinoma. Med. Oncol. 2011, 28:804-809.
312. Morgan T.R., Mandayam S., Jamal M.M. Alcohol and hepatocellular carcinoma. Gastroenterology 2004, 127:S87-S96.
313. Ura S., Honda M., Yamashita T., Ueda T., Takatori H., Nishino R., Sunakozaka H., Sakai Y., Horimoto K., Kaneko S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009, 49:1098-1112.
314. Ladeiro Y., Couchy G., Balabaud C., Bioulac-Sage P., Pelletier L., Rebouissou S., Zucman-Rossi J. MicroRNA profiling in hepatocellular tumours is associated with clinical features and oncogene/tumour suppressor gene mutations. Hepatology 2008, 47:1955-1963.
315. Braconi C., Valeri N., Gasparini P., Huang N., Taccioli C., Nuovo G., Suzuki T., Croce C.M., Patel T. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin. Cancer Res. 2010, 16:957-966.
316. Niepmann M. Activation of hepatitis C virus translation by a liver-specific microRNA. Cell Cycle 2009, 8:1473-1477.
317. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309:1577-1581.
318. Pogribny I.P., Tryndyak V.P., Boyko A., Rodriguez-Juarez R., Beland F.A., Kovalchuk O. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat. Res. 2007, 619:30-37.
319. Wang B., Majumder S., Nuovo G., et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009, 50:1152-1161.
320. Chang T.C., Yu D., Lee Y.S., Wentzel E.A., Arking D.E., West K.M., Dang C.V., Thomas-Tikhonenko A., Mendell J.T. Widespread microRNA repression by Myc contributes to carcinogenesis. Nat. Genet. 2008, 40:43-50.
321. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., Chang T.C., Vivekanandan P., Torbenson M., Clark K.R., Mendell J.R., Mendell J.T. Therapeutic microRNA delivery suppresses carcinogenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
322. Lin J., Huang S., Wu S., Ding J., Zhao Y., Liang L., Tian Q., Zha R., Zhan R., He X. MicroRNA-423 promotes cell growth and regulates G1/S transition by targeting p21Cip1/Waf1 in hepatocellular carcinoma. Carcinogenesis 2011, 32:1641-1647.
323. Fornari F., Gramantieri L., Ferracin M., Veronese A., Sabbioni S., Calin G.A., Grazi G.L., Giovannini C., Croce C.M., Bolondi L., Negrini M. miR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008, 27:5651-5661.
324. Braconi C., Henry J.C., Kogure T., Schmittgen T., Patel T. The role of microRNAs in human liver cancers. Semin. Oncol. 2011, 38:752-763.
325. Xu T., Zhu Y., Xiong Y., Ge Y.Y., Yun J.P., Zhuang S.M. MicroRNA-195 suppresses tumourigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009, 50:113-121.
326. Gramantieri L., Ferracin M., Fornari F., Veronese A., Sabbioni S., Liu C.G., Calin G.A., Giovannini C., Ferrazzi E., Grazi G.L., Croce C.M., Bolondi L., Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007, 67:6092-6099.
327. Wong Q.W., Lung R.W., Law P.T., Lai P.B., Chan K.Y., To K.F., Wong N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008, 135:257-269.
328. Li Y., Tan W., Neo T.W., Aung M.O., Wasser S., Lim S.S., Tan T.M. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci. 2009, 100:1234-1242.
329. Stanelle J., Putzer B.M. E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol. Med. 2006, 12:177-185.
330. Wong Q.W., Ching A.K., Chan A.W., Choy K.W., To K.F., Lai P.B., Wong N. MiR-222 over-expression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signalling. Clin. Cancer Res. 2010, 16:867-875.
331. Garofalo M., Di Leva G., Romano G., Nuovo G., Suh S.S., Ngankeu A., Taccioli C., Pichiorri F., Alder H., Secchiero P., Gasparini P., Gonelli A., Costinean S., Acunzo M., Condorelli G., Croce C.M. miR-221&222 regulate TRAIL resistance and enhance tumourigenicity through PTEN and TIMP3 down-regulation. Cancer Cell 2009, 16:498-509.
332. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumour suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
333. Pogribny I.P., Muskhelishvili L., Tryndyak V.P., Beland F.A. The tumour-promoting activity of 2-acetylaminofluorene is associated with disruption of the p53 signalling pathway and the balance between apoptosis and cell proliferation. Toxicol. Appl. Pharmacol. 2009, 235:305-311.
334. Wang B., Hsu S.H., Majumder S., Kutay H., Huang W., Jacob S.T., Ghoshal K. TGFbeta-mediated up-regulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010, 29:1787-1797.
335. Kim T., Veronese A., Pichiorri F., Lee T.J., Jeon Y.J., Volinia S., Pineau P., Marchio A., Palatini J., Suh S.S., Alder H., Liu C.G., Dejean A., Croce C.M. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 2011, 208:875-883.
336. Zheng F., Liao Y.J., Cai M.Y., Liu Y.H., Liu T.H., Chen S.P., Bian X.W., Guan X.Y., Lin M.C., Zeng Y.X., Kung H.F., Xie D. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012, 61:278-289.
337. Pineau P., Volinia S., McJunkinc K., Marchioa A., Battistone C., Terrisf B. miR-221 over-expression contributes to liver carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:264-269.
338. Fan C.G., Wang C.M., Tian C., Wang Y., Li L., Sun W.S., Li R.F., Liu Y.G. miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Oncol. Rep. 2011, 26:1281-1286.
339. X.X. He, Y. Chang, F.Y. Meng, M.Y. Wang, Q.H. Xie, F. Tang, P.Y. Li, Y.H. Song, J.S. Lin, MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo, Oncogene, in press, doi:. doi:10.1038/onc.2011.500.
340. Liu A.M., Poon R.T., Luk J.M. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem. Biophys. Res. Commun. 2010, 394:623-627.
341. Huang X.H., Chen J.S., Wang Q., Chen X.L., Wen L., Chen L.Z., Bi J., Zhang L.J., Su Q., Zeng W.T. miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J. Pathol. 2011, 225:463-472.
342. Li N., Fu H., Tie Y., Hu Z., Kong W., Wu Y., Zheng X. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009, 275:44-53.
343. Huang, He X., Ding J., Liang L., Zhao Y., Zhang Z., Yao X., Pan Z., Zhang P., Li J., Wan D., Gu J. Up-regulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumour-suppressive activities in human hepatocellular carcinoma cells. Int. J. Cancer 2008, 123:972-978.
344. Petrocca F., Vecchione A., Croce C.M. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signalling. Cancer Res. 2008, 68:8191-8194.
345. Gramantieri L., Fornari F., Ferracin M., Veronese A., Sabbioni S., Calin G.A., Grazi G.L., Croce C.M., Bolondi L., Negrini M. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumour multifocality. Clin. Cancer Res. 2009, 15:5073-5081.
346. Su H., Yang J.R., Xu T., Huang J., Xu L., Yuan Y., Zhuan S.M. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumourigenicity. Cancer Res. 2009, 69:1135-1142.
347. Xiong Y., Fang J.H., Yun J.P., Yang J., Zhang Y., Jia W.H., Zhuang S.M. Effects of MicroRNA-29 on apoptosis, tumourigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51:836-845.
348. Lin C.J., Gong H.Y., Tseng H.C., Wang W.L., Wu J.L. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem. Biophys. Res. Commun. 2008, 375:315-320.
349. Wang C.M., Wang Y., Fan C.G., Xu F.F., Sun W.S., Liu Y.G., Jia J.H. miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2011, 411:586-592.
350. Yoon S., Kim T.H., Natarajan A., Wang S.S., Choi J., Wu J., Zern M.A., Venugopal S.K. Acute liver injury upregulates microRNA-491-5p in mice, and its over-expression sensitizes Hep G2 cells for tumour necrosis factor-alpha-induced apoptosis. Liver Int. 2010, 30:376-387.
351. Takata, Otsuka M., Kojima K., Yoshikawa T., Kishikawa T., Yoshida H., Koike K. MicroRNA-22 and microRNA-140 suppress NF-κB activity by regulating the expression of NF-κB coactivators. Biochem. Biophys. Res. Commun. 2011, 411:826-831.
352. Zhang J.F., He M.L., Fu W.M., Wang H., Chen L.Z., Zhu X., Chen Y., Xie D., Lai P., Chen G., Lu G., Lin M.C., Kung H.F. Primate-specific miRNA-637 inhibits carcinogenesis in hepatocellular carcinoma by disrupting stat3 signalling. Hepatology 2011, 54:2137-2148.
353. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signalling pathway: clinical implications. Clin. Cancer Res. 2007, 13:1362-1366.
354. I. Koturbash, S. Melnyk, S.J. James, F.A. Beland, I.P. Pogribny, Role of epigenetic and miR-22 and miR-29b alterations in the downregulation of Mat1a and Mthfr genes in early preneoplastic livers in rats induced by 2-acetylaminofluorene, Mol. Carcinog., in press, doi:. doi:10.1002/mc.21861.
355. Kim, Veronese F., Pichiorri T.J., Lee Y.J., Jeon S., Volinia P., Pineau A., Marchio J., Palatini S.S., Suh H., Alder C.G., Liu A., Dejean A., Croce C.M. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 2011, 208:875-883.
356. Zhou Y.M., Cao L., Li B., Zhang R.X., Sui C.J., Yin Z.F., Yang J.M. Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma. Ann. Surg. Oncol. 2012, 19:1700-1706.
357. Zheng F., Liao Y.J., Cai M.Y., Liu Y.H., Liu T.H., Chen S.P., Bian X.W., Guan X.Y., Lin M.C., Zeng Y.X., Kung H.F., Xie D. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2011, 61:278-289.
358. Ji J., Zhao L., Budhu A., Forgues M., Jia H.L., Qin L.X., Ye Q.H., Yu J.S., Shi X., Tang Z.Y., Wang H.W. Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J. Hepatol. 2010, 5:690-697.
359. Lan F.F., Wang H., Chen Y.C., Chan C.Y., Ng S.S., Li K., Xie D., He M.L., Lin M.C., Kung H.F. Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by down-regulation of c-Myc and up-regulation of p16(INK4A). Int. J. Cancer 2011, 128:319-331.
360. Jong C.L., Norman K.L., Sarnow P. Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. Cold Spring Harb. Symp. Quant. Biol. 2006, 71:369-376.
361. Henke J.I., Goergen D., Zheng J., Song Y., Schüttler C.G., Fehr C., Jünemann C., Niepmann M. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 2008, 27:3300-3310.
362. Zhang R., Wang L., Yu G.R., Zhang X., Yao L.B., Yang A.G. MicroRNA-122 might be a double-edged sword in hepatocellular carcinoma. Hepatology 2009, 50:1322-1323.
363. Tsai W.C., Hsu P.W., Lai T.C., Chau G.Y., Lin C.W., Chen C.M., Lin C.D., Liao Y.L., Wang J.L., Chau Y.P., Hsu M.T., Hsiao M., Huang H.D., Tsou A.P. MicroRNA-122, a tumour suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009, 49:1571-1582.
364. Ding J., Huang S., Wu S., Zhao Y., Liang L., Yan M., Ge C., Yao J., Chen T., Wan D., Wang H., Gu J., Yao M., Li J., Tu H., He X. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat. Cell Biol. 2010, 12:390-399.
365. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., Parsons J.T., Horwitz A.R. Cell migration: integrating signals from front to back. Science 2003, 302:1704-1709.
366. Han Z.B., Chen H.Y., Fan J.W., Wu J.Y., Tang H.M., Peng Z.H. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J. Cancer Res. Clin. Oncol. 2012, 138:153-161.
367. Li D., Liu X., Lin L., Hou J., Li N., Wang C., Wang P., Zhang Q., Zhang P., Zhou W., Wang Z., Ding G., Zhuang S.M., Zheng L., Tao W., Cao X. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J. Biol. Chem. 2001, 286:36677-36685.
368. H.Y. Chen, Z.B. Han, J.W. Fan, J. Xia, J.Y. Wu, G.Q. Qiu, H.M. Tang, Z.H. Peng. miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med. Oncol., in press.
369. Coulouarn C., Factor V.M., Andersen J.B., Durkin M.E., Thorgeirsson S.S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28:3526-3536.
370. Luk J.M., Burchard J., Zhang C., Liu A.M., Wong K.F., Shek F.H., Lee N.P., Fan S.T., Poon R.T., Ivanovska I., Philippar U., Cleary M.A., Buser C.A., Shaw P.M., Lee C.N., Tenen D.G., Dai H., Mao M. MDLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. Biol. Chem. 2011, 286:30706-30713.
371. Toffanin S., Hoshida Y., Lachenmayer A., Villanueva A., Cabellos L., Minguez B., Savic R., Ward S.C., Thung S., Chiang D.Y., Alsinet C., Tovar V., Roayaie S., Schwartz M., Bruix J., Waxman S., Friedman S.L., Golub T., Mazzaferro V., Llovet J.M. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of mir-517a. Gastroenterology 2011, 140:1618-1628.
372. Wu X., Wu S., Tong L., Luan T., Lin L., Lu S., Zhao W., Ma Q., Liu H., Zhong Z. miR-122 affects the viability and apoptosis of hepatocellular carcinoma cells. Scand. J. Gastroenterol. 2009, 44:1332-1339.
373. Xu T., Zhu Y., Wei Q.K., Yuan Y., Zhou F., Ge Y.Y., Yang J.R., Su H., Zhuang S.M. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 2008, 29:2126-2131.
374. Gao Y., He Y., Ding J., Jiang Y., Jia S., Xia W., Zhao J., Lu M., Gu Z., Gao Y. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis 2009, 30:2064-2069.
375. Qi P., Dou T.H., Geng L., Zhou F.G., Gu X., Wang H., Gao C.F. Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. Hum. Immunol. 2010, 71:621-626.
376. Li X.D., Li Z.G., Song X.X., Liu C.F. A variant in microRNA-196a2 is associated with susceptibility to hepatocellular carcinoma in Chinese patients with cirrhosis. Pathology 2010, 42:669-673.
377. L.S. Zhang, W.B. Liang, L.B. Gao, H.Y. Li, L.J. Li, P.Y. Chen, Y. Liu, T.Y. Chen, J.G. Han, Y.G. Wei, L. Zhang, Association between pri-miR-218 polymorphism and risk of hepatocellular carcinoma in a Han Chinese population, DNA Cell Biol., in press.
378. Xu Y., Liu L., Liu J., Zhang Y., Zhu J., Chen J., Liu S., Liu Z., Shi H., Shen H., Hu Z. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int. J. Cancer 2011, 128:412-417.
379. Xie Q.H., He X.X., Chang Y., Sun S.Z., Jiang X., Li P.Y., Lin J.S. MiR-192 inhibits nucleotide excision repair by targeting ERCC3 and ERCC4 in HepG2.2.15 cells. Biochem. Biophys. Res. Commun. 2011, 410:440-445.
380. Valeri N., Gasparini P., Fabbri M., Braconi C., Veronese A., Lovat F., Adair B., Vannini I., Fanini F., Bottoni A., Costinean S., Sandhu S.K., Nuovo G.J., Alder H., Gafa R., Calore F., Ferracin M., Lanza G., Volinia S., Negrini M., McIlhatton M.A., Amadori D., Fishel R., Croce C.M. Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6982-6987.
381. Datta J., Kutay H., Nasser M.W., Nuovo G.J., Wang B., Majumder S., Liu C.G., Volinia S., Croce C.M., Schmittgen T.D., Ghoshal K., Jacob S.T. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008, 68:5049-5058.
382. Bai S., Nasser M.W., Wang B., Hsu S.H., Datta J., Kutay H., Yadav A., Nuovo G., Kumar P., Ghoshal K. MicroRNA-122 inhibits tumourigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem. 2009, 284:32015-32027.
383. Xu Y., Xia F., Ma L., Shan J., Shen J., Yang Z., Liu J., Cui Y., Bian X., Bie P., Qian C. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett. 2011, 310:160-169.
384. Ji J., Shi J., Budhu A., Yu Z., Forgues M., Roessler S., Ambs S., Chen Y., Meltzer P.S., Croce C.M., Qin L.X., Man K., Lo C.M., Lee J., Ng I.O., Fan J., Tang Z.Y., Sun H.C., Wang X.W. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 2009, 361:1437-1447.
385. Mínguez B., Tovar V., Chiang D., Villanueva A., Llovet J.M. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr. Opin. Gastroenterol. 2009, 25:186-194.
386. Wörns M.A., Galle P.R. Future perspectives in hepatocellular carcinoma. Dig. Liver Dis. 2010, 42S:S302-S309.
387. Epstein R.J., Leung T.W. Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin. Cancer Res. 2007, 13:11-17.
388. Huynh H., Ngo V.C., Koong H.N., Poon D., Choo S.P., Thng C.H., Chow P., Ong H.S., Chung A., Soo K.C. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J. Cell. Mol. Med. 2009, 13:2673-2683.
389. Newell P., Toffanin S., Villanueva A., Chiang D.Y., Minguez B., Cabellos L., Savic R., Hoshida Y., Lim K.H., Melgar-Lesmes P., Yea S., Peix J., Deniz K., Fiel M.I., Thung S., Alsinet C., Tovar V., Mazzaferro V., Bruix J., Roayaie S., Schwartz M., Friedman S.L., Llovet J.M. Ras pathway activation in hepatocellular carcinoma and anti-tumoural effect of combined sorafenib and rapamycin in vivo. J. Hepatol. 2009, 51:725-733.
390. Thomas M.B., Morris J.S., Chadha R., Iwasaki M., Kaur H., Lin E., Kaseb A., Glover K., Davila M., Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 2009, 27:843-850.
391. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's achilles' heel. Cancer Cell 2008, 13:472-482.
392. Israël M., Schwartz L. The metabolic advantage of tumor cells. Mol. Cancer 2011, 10:70.
393. Zhao Y., Liu H., Riker A.I., Fodstad O., Ledoux S.P., Wilson L.G.L., Tan M. Emerging metabolic targets in cancer therapy. Front. Biosci. 2012, 16:1844-1860.
394. Cao Z., Fan-Minogue H., Bellovin D.I., Yevtodiyenko A., Arzeno J., Yang Q., Gambhir S.S., Felsher D.W. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res. 2011, 71:2286-2297.
395. Relja B., Meder F., Wang M., Blaheta R., Henrich D., Marzi I., Lehnert M. Simvastatin modulates the adhesion and growth 38 of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int. J. Oncol. 2011, 879-885.
396. Relja, Meder F., Wilhelm K., Henrich D., Marzi I., Lehnert M. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int. J. Mol. Med. 2010, 26:735-741.
397. Shimizu M., Yasuda Y., Sakai H., Kubota M., Terakura D., Baba A., Ohno T., Kochi T., Tsurumi H., Tanaka T., Moriwaki H. Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. BMC Cancer Jun. 28 2011, 11:281.